Characteristics of two mouse bcr-abl-transformed cell lines: I. General properties of the cells

Folia Biologica

Volumn 51, Issue 1, 2005, Pages 12-18

  Sobotkova E ^a   Ludvikova V ^a   Petrackova M ^a   Duskova M ^a   Smetana, K ^a   Jelinek F ^a   Marinov, I ^a   Vonka, Vladimír ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BIOLOGICAL MARKER; ANTINEOPLASTIC AGENT; HLA ANTIGEN CLASS 1; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TUMOR MARKER;

ANIMAL CELL; ARTICLE; BLAST CELL; CARCINOGENICITY; CELL ACTIVITY; CELL AGING; CELL LINE; CELL STRUCTURE; CELL TRANSFORMATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOLOGY; FREQUENCY ANALYSIS; GENETIC POLYMORPHISM; GIANT CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; ANIMAL; BAGG ALBINO MOUSE; CANCER INVASION; CANCER TRANSPLANTATION; CELL PROLIFERATION; CELL SHAPE; COMPARATIVE STUDY; DOWN REGULATION; DRUG EFFECT; DRUG RESISTANCE; GENETICS; LEUKEMIA; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSPLANTATION;

ANIMALIA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL AGING; CELL LINE, TRANSFORMED; CELL PROLIFERATION; CELL SHAPE; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HISTOCOMPATIBILITY ANTIGENS CLASS I; LEUKEMIA; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PIPERAZINES; PYRIMIDINES; TUMOR MARKERS, BIOLOGICAL;

EID: 14944355295     PISSN: 00155500     EISSN: 25337602     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Algarra, I., Garcia-Lora, A., Cabrera, T., Ruiz-Cabello, F., Garrido, F. (2004) The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol. Immunother. 53, 904-910.
2. Bocchia, M., Korontsvit, T., Xu, Q., Mackinnon, S., Yang, S. Y., Sette, A., Scheinberg, D. A. (1996) Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 87, 3587-3592.
3. Bubeník, J., Vonka, V. (2003) MHC class I status of tumours and design of immunotherapeutic strategies. Immunol. Lett. 90, 177-178.
4. Cathcart, K., Pinilla-Ibarz, J., Korontsvit, T., Schwartz, J., Zakhaleva, V., Papadopoulos, E. B., Scheinberg, D. A. (2004) A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 103, 1037-1042.
5. Daley, G. Q., Baltimore, D. (1988) Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc. Natl. Acad Sci. USA 85, 9312-9316.
6. Deng, M., Daley, G. (2001) Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukaemia. Blood 97, 3491-3497.
7. Graner, M. W., Zeng, Y., Feng, H., Katsanis, E. (2003) Tumor derived chaperone-rich cell lysates are effective therapeutic vaccines against variety of cancers. Cancer Immunol. Immunother. 52, 226-234.
8. He, L., Feng, H., Raymond, A., Kreeger, M., Zeng, Y., Graner, M., Whitesell, L., Katsanis, E. (2001) Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice. Cancer Immunol. Immunother. 50, 31-40.
9. Holyoake, D. T. (2001) Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory. Br J. Haematol. 113, 11-23.
10. Konopka, J. B., Witte, O. N. (1985) Activation of the abl oncogene in murine and human leukemias. Biochim. Biophys. Acta 823, 1-17.
11. Leeksma, O. C., Kessler, J. H., Huijbers, I. J., Ten Bosch, G. J., Melief, C. J. (2000) BCR-ABL directed immunotherapy: a virtual reality? Leuk. Lymphoma 38, 175-181.
12. McLaughlin, J., Chianese, E., Witte, O. N. (1987) In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc. Natl. Acad. Sci. USA 84, 6558-6562.
13. Melo, J. V., Deininger, M. W. (2004) Biology of chronic myelogenous leukaemia - signaling pathways of initiation and transformation. Hematol. Oncol. Clin. North. Am. 18, 545-568.
14. Norbury, L. C., Clark, R. E., Christmas, S. E. (2000) b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia. Br. J. Haematol. 109, 616-621.
15. Ochs, R. L. (1998) Method used to study structure and function of the nucleolus. Methods Cell Biol. 53, 303-321.
16. Osman, Y., Takahashi, M., Zheng, Z., Koike, T., Toba, K., Liu, A., Furukawa, T., Aoki, S., Aizawa, Y. (1999) Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients. Leukemia 13, 166-174.
17. Palacios, R., Steinmetz, M. (1985) Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 41, 727-734.
18. Pinilla-Ibarz, J., Cathcart, K., Korontsvit, T., Soignet, S., Bocchia, M., Caggiano, J., Lai, L., Jimenez, J., Kolitz, J., Scheinberg, D. A. (2000) Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 95, 1781-1787.
19. Smetana, K. (1980) Nucleoli in maturing blood cells. Topic. Rev. Haematol. 1, 115-137.
20. Smetana, K., Lejnar, J., Potměšil, M. (1967) A note to the demonstration of DNA in nuclei of blood cells in smear preparations. Folia Haematol. 88, 305-317.
21. Smetana, K., Jirásková, I., Perlaky, L., Busch, H. (1999) The silver reaction of nucleolar proteins in the main structural compartments of ring shaped nucleoli in smear preparation. Acta Histochem. 101, 167-183.
22. Smetana, K. (2002) Structural features of nucleoli in blood, leukemic, lymphoma and myeloma cells. Eur. J. Histochem. 46, 125-132.
23. Smetana, K. (2003) To the nucleolar structure and cytochemistry (Nucleoli as useful markers of various cell states). Recent Res. Develop. Life Sci. 1, 253-263.
24. Ten Bosch, G. J., Toornvliet, A. C., Friede, T., Melief, C. J., Leeksma, O. C. (1995) Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells. Leukemia 9, 1344-1348.
25. Yotnda, P., Firat, H., Garcia-Pons, F., Garcia, Z., Gourru, G., Vernant, J. P., Lemonnier, F. A., Leblond, V., Langlade-Demoyen, P. (1998) Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J. Clin. Invest. 101, 2290-2296.
26. + murine leukaemia. Int. J. Cancer 110, 251-259.